A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours.

A Phase I/II clinical trial, NCT06682780, is being conducted to evaluate the safety and tolerability of LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours. The study aims to determine the recommended phase 2 dose (RP2D) or Maximum Tolerated Dose (MTD) for LM-2417. The trial is not yet recruiting participants and is expected to enroll 320 individuals with advanced solid tumors. The study is being conducted in China and is led by LaNova Medicines Limited. [Extracted from the article]